319 related articles for article (PubMed ID: 22361928)
1. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
Sadowska AM
Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
[TBL] [Abstract][Full Text] [Related]
3. [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness].
Gillissen A
Pneumologie; 2011 Sep; 65(9):549-57. PubMed ID: 21761386
[TBL] [Abstract][Full Text] [Related]
4. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
5. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine.
De Lisle RC; Roach E; Jansson K
Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G577-84. PubMed ID: 17615175
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
7. Role of N-acetylcysteine in the management of COPD.
Sadowska AM; Verbraecken J; Darquennes K; De Backer WA
Int J Chron Obstruct Pulmon Dis; 2006; 1(4):425-34. PubMed ID: 18044098
[TBL] [Abstract][Full Text] [Related]
8. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
9. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
11. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
12. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress.
Jang MK; Kim SH; Lee KY; Kim TB; Moon KA; Park CS; Bae YJ; Zhu Z; Moon HB; Cho YS
Biochem Biophys Res Commun; 2010 Feb; 393(1):137-43. PubMed ID: 20117097
[TBL] [Abstract][Full Text] [Related]
14. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats.
Cai S; Chen P; Zhang C; Chen JB; Wu J
Respirology; 2009 Apr; 14(3):354-9. PubMed ID: 19341424
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
Calzetta L; Matera MG; Rogliani P; Cazzola M
Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV).
Mata M; Morcillo E; Gimeno C; Cortijo J
Biochem Pharmacol; 2011 Sep; 82(5):548-55. PubMed ID: 21635874
[TBL] [Abstract][Full Text] [Related]
17. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Ehre C; Rushton ZL; Wang B; Hothem LN; Morrison CB; Fontana NC; Markovetz MR; Delion MF; Kato T; Villalon D; Thelin WR; Esther CR; Hill DB; Grubb BR; Livraghi-Butrico A; Donaldson SH; Boucher RC
Am J Respir Crit Care Med; 2019 Jan; 199(2):171-180. PubMed ID: 30212240
[TBL] [Abstract][Full Text] [Related]
18. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine counteracts oxidative stress and prevents hCG-induced apoptosis in rat Leydig cells through down regulation of caspase-8 and JNK.
Aggarwal A; Misro MM; Maheshwari A; Sehgal N; Nandan D
Mol Reprod Dev; 2010 Oct; 77(10):900-9. PubMed ID: 20824644
[TBL] [Abstract][Full Text] [Related]
20. [Acetylcysteine in the treatment of severe COPD].
Dekhuijzen PN
Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1222-6. PubMed ID: 16796172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
